What Are the Common Symptoms of Sexually Transmitted Infections in Women?

Sexually transmitted infections (STIs) can present with a wide range of signs and symptoms in women—many of which are subtle, nonspecific, or entirely absent. Asymptomatic infection is common, particularly with chlamydia, gonorrhea, and human papillomavirus (HPV), contributing to delayed diagnosis and increased risk of complications such as pelvic inflammatory disease (PID), infertility, ectopic pregnancy, and chronic pelvic pain.

When symptoms do occur, they often involve the lower genital tract. Common manifestations include abnormal vaginal discharge—characterized by changes in color (e.g., yellow, green, or gray), consistency (e.g., purulent, frothy, or cottage cheese–like), odor (notably fishy in bacterial vaginosis or trichomoniasis), or volume. Women may also report pruritus vulvae, dysuria (painful urination), or dyspareunia (pain during intercourse). External genital lesions—such as painful ulcers (typical of primary herpes simplex virus [HSV] infection), painless chancres (associated with syphilis), or verrucous growths (indicative of HPV-related condyloma acuminata)—may be observed on inspection.

Lower abdominal or pelvic pain—especially if bilateral and accompanied by fever, cervical motion tenderness, or uterine/adnexal tenderness—should raise suspicion for upper genital tract involvement, including PID. Menstrual irregularities, postcoital bleeding, or intermenstrual spotting may accompany infections such as chlamydia or gonorrhea, particularly when endometritis or cervicitis is present. Systemic features—including low-grade fever, malaise, or lymphadenopathy—can occur in advanced or disseminated disease, such as secondary syphilis or disseminated gonococcal infection.

It is critical to emphasize that symptom-based screening is insufficient for STI detection. Routine nucleic acid amplification testing (NAAT) for *Chlamydia trachomatis* and *Neisseria gonorrhoeae*, along with serologic testing for syphilis and HIV, is recommended for sexually active women under age 26 and those at increased risk—regardless of symptom status. Early identification and treatment not only mitigate individual morbidity but also reduce community transmission and long-term reproductive sequelae.